MedTrace Logo

A Randomized Study to Evaluate the Effects of CTP-543 on the QT/QTc Intervals in Health Volunteers

NCT05192369 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2022-03-04

No results posted yet for this study

Summary

This is a four-arm, randomized, crossover, placebo and active controlled study to evaluate of the effect of therapeutic and supratherapeutic doses of CTP-543 on the QT/QTc intervals in healthy volunteers

Conditions

  • Healthy Volunteers

Interventions

DRUG

CTP-543

CTP-543 12 mg (1 x 12 mg tablet), dosed with water

DRUG

CTP-543

CTP-543 48 mg (4 x 12 mg tablet) dosed with water

DRUG

Moxifloxacin

Moxifloxacin (1 x 400 mg tablet) dosed with water

DRUG

Placebo

Placebo (1 tablet) dosed with water

Sponsors & Collaborators

  • Concert Pharmaceuticals

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-04
Primary Completion
2022-01-28
Completion
2022-01-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05192369 on ClinicalTrials.gov